Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Vick

Premium
Silence Therapeutics has named Jeffrey Vick as its new CEO.
 
The company said it appointed Vick to “strengthen its core management team as [it] seeks to expand its business partnerships.” Silence has not had a CEO since it began refocusing on RNAi therapeutics in 2004 (see RNAi News, 7/29/2005).
 
Vick previously served in senior management at DepoTech, was vice president of corporate development for Cytoyia, vice president of business development at Genset, and vice president of corporate development and intellectual property at Centelion.
 
He holds a BS in chemistry from the University of Virginia, and an MS in chemistry from the University of California, San Diego. He also holds an MBA from Stanford Graduate School of Business.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.